Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM

Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT.

The role of HLA amino acid (AA) polymorphism for the outcome of hematopoietic cell transplantation (HCT) is controversial, in particular for HLA class II. Here, we investigated this question in nonpermissive HLA-DPB1 T-cell epitope (TCE) mismatches reflected by numerical functional distance (FD) scores, assignable to all HLA-DPB1 alleles based on the combined impact of 12 polymorphic AAs. We ca...

HLA-DPB1 and TAP1 polymorphisms in sarcoidosis.

HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.

The MHC is central to the adaptive immune response. The human MHC class II is encoded by three different isotypes, HLA-DR, -DQ, and -DP, each being highly polymorphic. In contrast to HLA-DR, the intracellular assembly and trafficking of HLA-DP molecules have not been studied extensively. However, different HLA-DP variants can be either protective or risk factors for infectious diseases (e.g. he...

Non-Permissive HLA-DPB1 Disparity is a Significant Independent Risk Factor for Mortality after Unrelated Hematopoietic Stem Cell Transplantation Running Title: Nonpermissive HLA-DPB1 disparity in unrelated HSCT

Hematology and Bone Marrow Transplantation Unit, Department of Oncology, San Raffaele Scientific Institute, Milano, Italy; Biostatistics Unit, Department of Health Sciences (DISSAL), University of Genova, Italy; Immunogenetics Laboratory, Unit of Immunohematology and Blood Transfusion, Division of Regenerative Medicine and Stem Cell Therapy, San Raffaele Scientific Institute, Milano, Italy; San...

Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.

We examined current outcomes of unrelated donor allogeneic hematopoietic cell transplantation (HCT) to determine the clinical implications of donor-recipient HLA matching. Adult and pediatric patients who had first undergone myeloablative-unrelated bone marrow or peripheral blood HCT for acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, and myelodysplastic ...